Skip to main content

September 2015

Novo Nordisk announced the headline results from the second phase 3a trial for semaglutide, SUSTAIN3. Semaglutide is a new GLP-1 analogue administered subcutaneously once weekly. The trial investigated the efficacy and safety of 1.0 mg semaglutide compared with 2.0 mg exenatide once-weekly after 56 weeks of treatment added on to 1-2 oral antidiabetic drugs in 813 people with type 2 diabetes.

Researchers have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves. The study was published in PLOS One.

[adsense:336x280:8701650588]

A new study warns that if you often feel dizzy, faint or light-headed after getting up, these symptoms could indicate greater risk of developing brain disease such as Parkinson's or dementia, and even an increased risk of death. The findings appeared in the online issue of the journal Neurology.

Impax Laboratories, Inc, a specialty pharmaceutical company, has received US Food and Drug Administration (FDA) approval for generic Mestinon Timespan tablets (pyridostigmine bromide extended release), 180 mg. The company is going for commercialisation of this product.

New research suggests that some, but not all adults who have experienced sexual or physical abuse as children go on to develop long term depression, this could partly be due to their specific genetic make up. Researchers also found that the same gene variant that can make a person sad in one context, can trigger happiness in another context. The research was published in the British Journal of Psychiatry Open.